Patent US5830178A successfully refreshed from Google Patents.
US5830178A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide
Assignee: Micro Therapeutics Inc
•
Filing: 1996-10-11
•
Granted: 1998-11-03
•
Expires: 2016-10-11
Abstract
Abstract Disclosed are novel methods for embolizing blood vessels which are particularly suited for treating vascular lesions via catheter delivery of an embolic composition comprising a biocompatible polymer and an embolic solvent.
Inventors
- 👤 Michael L. Jones
- 👤 Richard J. Greff
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 19:54
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/50; A61K47/69; A61K47/6957
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
75 words
A method for intra-vascular delivery to a mammal of an embolic composition while inhibiting vasospasms in the mammal which method comprises: (a) selecting an embolic composition comprising a biocompatible, water insoluble polymer and an embolic solvent; and (b) intra-vascularly injecting the composition selected in (a) above into the mammal at a flow rate such that the concentration of the embolic solvent in a given blood volume is maintained at a level insufficient to initiate vasospasms.
Claim 2
Independent Claim
75 words
A method for intra-vascular delivery to a mammal of an embolic composition while inhibiting vasospasms in the mammal which method comprises: (a) selecting an embolic composition comprising a biocompatible, water insoluble polymer and an embolic solvent; and (b) intra-vascularly injecting the composition selected in (a) above into the mammal at a flow rate such that the concentration of the embolic solvent in a given blood volume is maintained at a level insufficient to initiate vasospasms.
Claim 3
Dependent Claim
12 words
The method according to claim 1 wherein said embolic solvent is dimethylsulfoxide.
Claim 4
Dependent Claim
15 words
The method according to claim 1 wherein the embolic composition further comprises a contrast agent.
Claim 5
Dependent Claim
16 words
The method according to claim 3 wherein the contrast agent is a water insoluble contrast agent.
Claim 6
Dependent Claim
26 words
The method according to claim 4 wherein said water insoluble contrast agent is selected from the group consisting of tantalum, tantalum oxide, tungsten and barium sulfate.
Claim 7
Dependent Claim
14 words
The method according to claim 4 wherein said water insoluble contrast agent is tantalum.
Claim 8
Dependent Claim
40 words
The method according to claim 1 wherein said biocompatible polymer is selected from the group consisting of cellulose acetates, ethylene vinyl alcohol copolymers, hydrogels, polyacrylonitrile, polyvinylacetate, cellulose acetate butyrate, nitrocellulose, copolymers of urethane/carbonate, copolymers of styrene/maleic acid, and mixtures thereof.
Claim 9
Dependent Claim
17 words
The method according to claim 6 wherein said biocompatible polymer is an ethylene and vinyl alcohol copolymer.
Claim 10
Dependent Claim
23 words
The method according to claim 4 wherein said water insoluble contrast agent has an average particle size of about 10 microns or less.
Claim 11
Independent Claim
300 words
A method for the catheter delivery of an embolic composition comprising a biocompatible polymer, a water insoluble biocompatible contrast agent, and an embolic solvent to an intra-vascular injection site of a mammal which method comprises: (a) select a microcatheter comprising a luer hub and a delivery means; (b) insert the delivery means of the microcatheter selected in (a) above into a to-be-embolized vascular site of a mammal and confirming placement in vivo with a water soluble contrast agent; (c) connect a syringe to the microcatheter luer hub and flushing any remaining water soluble contrast agent from the microcathether hub and delivery means with a solution comprising water; (d) add at least 0.50 cc of the embolic solvent to a second syringe; (e) attach the second syringe prepared in (d) above to the microcatheter luer hub and then inject no more than about 0.3 cc of the embolic solvent into vascular site to flush out the aqueous contrast agent; (f) remove the second syringe from the luer hub and then overfill/wash the luer hub of the microcatheter with the balance of the embolic solvent; (g) connect a syringe comprising an embolic composition to the microcatheter hub while ensuring that air does not enter into the hub during connection wherein the embolic composition comprises an embolic solvent, a biocompatible polymer dissolved in the solvent, and a water insoluble biocompatible contrast agent dispersed therein; (h) create a sharp interfacial boundary between the embolic solvent and the embolic composition; (i) inject over about a 1 minute period sufficient amount of the solution to displace the DMSO in the microcatheter; and (j) inject the embolic composition into the vascular site at a flow rate such that the concentration of the embolic solvent in a given blood volume is maintained at a level which inhibits vasospasms.
Claim 12
Independent Claim
300 words
A method for the catheter delivery of an embolic composition comprising a biocompatible polymer, a water insoluble biocompatible contrast agent, and an embolic solvent to an intra-vascular injection site of a mammal which method comprises: (a) select a microcatheter comprising a luer hub and a delivery means; (b) insert the delivery means of the microcatheter selected in (a) above into a to-be-embolized vascular site of a mammal and confirming placement in vivo with a water soluble contrast agent; (c) connect a syringe to the microcatheter luer hub and flushing any remaining water soluble contrast agent from the microcathether hub and delivery means with a solution comprising water; (d) add at least 0.50 cc of the embolic solvent to a second syringe; (e) attach the second syringe prepared in (d) above to the microcatheter luer hub and then inject no more than about 0.3 cc of the embolic solvent into vascular site to flush out the aqueous contrast agent; (f) remove the second syringe from the luer hub and then overfill/wash the luer hub of the microcatheter with the balance of the embolic solvent; (g) connect a syringe comprising an embolic composition to the microcatheter hub while ensuring that air does not enter into the hub during connection wherein the embolic composition comprises an embolic solvent, a biocompatible polymer dissolved in the solvent, and a water insoluble biocompatible contrast agent dispersed therein; (h) create a sharp interfacial boundary between the embolic solvent and the embolic composition; (i) inject over about a 1 minute period sufficient amount of the solution to displace the DMSO in the microcatheter; and (j) inject the embolic composition into the vascular site at a flow rate such that the concentration of the embolic solvent in a given blood volume is maintained at a level which inhibits vasospasms.
Claim 13
Dependent Claim
12 words
The method according to claim 10 wherein said embolic solvent is dimethylsulfoxide.
Claim 14
Dependent Claim
26 words
The method according to claim 10 wherein said water insoluble contrast agent is selected from the group consisting of tantalum, tantalum oxide, tungsten and barium sulfate.
Claim 15
Dependent Claim
14 words
The method according to claim 12 wherein said water insoluble contrast agent is tantalum.
Claim 16
Dependent Claim
40 words
The method according to claim 10 wherein said biocompatible polymer is selected from the group consisting of cellulose acetates, ethylene vinyl alcohol copolymers, hydrogels, polyacrylonitrile, polyvinylacetate, cellulose acetate butyrate, nitrocellulose, copolymers of urethane/carbonate, copolymers of styrene/maleic acid, and mixtures thereof.
Claim 17
Dependent Claim
17 words
The method according to claim 14 wherein said biocompatible polymer is an ethylene and vinyl alcohol copolymer.
Claim 18
Dependent Claim
23 words
The method according to claim 10 wherein said water insoluble contrast agent has an average particle size of about 10 microns or less.
Claim 19
Dependent Claim
26 words
The method according to claim 10 wherein the luer hub comprises multiple injection ports thereby permitting the attachment of multiple syringes simultaneously to the luer hub.
References Cited (Backward Citations)
WO1997004657A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-11-02 | 2002-05-04 | 2002-11-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-11-02 | 2006-05-04 | 2006-11-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-11-02 | 2010-05-04 | 2010-11-03 | $7700.00 | Window Closed / Lapsed |